“LL-37”的搜索结果，显示 201-210 项，共有 6975 项

1. 神经科- 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

2. 乳腺专科门诊- 临床试验- 妙佑医疗国际

   This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor ...

3. 神经科- 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

4. 神经科- 临床试验- 妙佑医疗国际

   ... 2 participants will also undergo MRI scanning, comprehensive cognitive ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying ...

5. 神经科- 临床试验- 妙佑医疗国际

   ... 2 or 3 meningioma as measured by 6-month PFS rate. A Study of Demyelinating ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) ...

6. 神经科- 临床试验- 妙佑医疗国际

   ... 2 participants will also undergo MRI scanning, comprehensive cognitive ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying ...

7. 神经科- 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

8. 神经科- 临床试验- 妙佑医疗国际

   ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme ...

9. 血液科- 临床试验- 妙佑医疗国际

   DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel ...

10. 神经科- 临床试验- 妙佑医疗国际

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...